×

Research and Markets: 07 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/jbx33n/07_2012) has announced the addition of the "07 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities" report to their offering.

This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in July 2012.

All companies include technology, market(s), key executive, and contact information.

Coverage Includes Innovations in a Broad Spectrum of Medical Technology Areas Including:

- Aesthetics/Dermatology Companies

- Biomaterials Companies

- Biotechnology/Cell Therapy Companies

- Cardiovascular Companies

- Dental Companies

- Diagnostics Companies

- Drug Delivery Companies

- Endocrine Companies

- Gastroenterology Companies

- Gynecology/Women's Health Companies

- Imaging Companies

- Neurology Companies

- Oncology Companies

- Ophthalmology Companies

- Orthopedics Companies

- Pain Management Companies

- Patient Management/Monitoring Companies

- Pharmaceutical Companies

- Respiratory Companies

- Spine Companies

- Surgery Companies

- Urology Companies

- Vascular Companies

- Wound Management Companies

Key Topics Covered:

Brief Technology Descriptions For Companies Covered

Fatty acid synthase (FASN) inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, for the treatment of chronic hepatitis C virus (HCV) and pancreatic, prostatic, breast, and colorectal tumors

A custom fit, rehabilitative body suit that offers instantaneous back pain relief, trains and conditions the body to prevent or rehabilitate from back injuries, and increases the overall long-term health of the spine

Biomaterial and regenerative medicine products for ophthalmological applications: ologen(R) Collagen Matrix, BioCornea, and Biolens

First-in-class, small molecule compounds that successfully manage and treat chronic pain, by inhibiting P2X3 receptors

Biomaterials for post-surgical adhesion prevention, scar prevention, wound care, and tissue reconstruction

Micro-catheter platform that uses a proprietary microfluidic design for the delivery of drug/active molecules directly to the central nervous system for the treatment of difficult/chronic neurological conditions

Protein therapeutics with extremely high target binding specificity for the treatment of cancer and immune-mediated diseases

An antibody that blocks the calcitonin gene-related peptide (CGRP) pathway to prevent migraine headaches

Drugs for the treatment of depression, anxiety, epilepsy, pain, glaucoma, spasticity, and a variety of other CNS-related conditions

Nanopharmaceuticals optimized to make drugs more effective and with fewer side effects

Unique diagnostic and monitoring technologies:

1-"Smart Optic Capillaroscope" for non-invasive diagnostics of early disorders in the smallest vessels-capillaries

2-"Hemodynamic Lab" for simultaneous diagnostics of the whole vascular system

3-"Meteolaboratory with Feedback Effect" for controlling influence of meteorological factors on the human organism

and much more....

For more information visit http://www.researchandmarkets.com/research/jbx33n/07_2012

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Biotechnology

Source: Research and Markets